Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
NIDDM
MCID: DBT026
MIFTS: 91

Diabetes Mellitus, Noninsulin-Dependent (NIDDM)

Categories: Genetic diseases, Endocrine diseases, Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Diabetes Mellitus, Noninsulin-Dependent

About this section

MalaCards integrated aliases for Diabetes Mellitus, Noninsulin-Dependent:

Name: Diabetes Mellitus, Noninsulin-Dependent 57 13 38 40
Insulin Resistance 57 29 55 6 73
Niddm 57 12 25 75 55
Diabetes Mellitus, Non-Insulin-Dependent 57 25 75 73
Type 2 Diabetes Mellitus 38 12 25 15
Diabetes Mellitus Type 2 76 75 29 6
Noninsulin-Dependent Diabetes Mellitus 57 25 75
Insulin Resistance, Severe, Digenic 57 13 6
Diabetes Mellitus, Type 2 57 25 44
Maturity-Onset Diabetes 57 25 75
T2d 57 25 75
Hypertension, Insulin Resistance-Related, Susceptibility to 57 6
Diabetes Mellitus, Noninsulin-Dependent, Association with 57 6
Diabetes Mellitus, Type 2, Susceptibility to 57 6
Insulin Resistance, Susceptibility to 57 6
Adult-Onset Diabetes Mellitus 25 75
Diabetes Mellitus, Type Ii 57 25
Type Ii Diabetes Mellitus 12 37
Type 2 Diabetes 25 63
Diabetes Mellitus, Non-Insulin-Dependent, Susceptibility to 57
Diabetes Mellitus, Noninsulin-Dependent, Susceptibility to 57
Diabetes Mellitus, Noninsulin-Dependent, Late Onset 57
Diabetes Mellitus, Noninsulin-Dependent, Late-Onset 6
Diabetes Mellitus, Type Ii, Susceptibility to 57
Diabetes Mellitus, Noninsulin-Dependent, 2 57
Hypertension, Insulin Resistance-Related 57
Non-Insulin-Dependent Diabetes Mellitus 12
Diabetes, Type Ii, Susceptibility to 6
Diabetes, Type 2, Susceptibility to 57
Maturity-Onset Diabetes Mellitus 25
Diabetes Mellitus, Type Ii; T2d 57
Diabetes Mellitus, Adult-Onset 25
Diabetes Mellitus Type Ii 75
Adult-Onset Diabetes 25
Diabetes Mellitus 73
Diabetes, Type 2 57
Diabetes Type 2 43
Aodm 25

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
diabetes mellitus, noninsulin-dependent:
Inheritance autosomal dominant inheritance
Onset and clinical course late onset


Classifications:

MalaCards categories:
Global: Genetic diseases Metabolic diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Diabetes Mellitus, Noninsulin-Dependent

About this section
MedlinePlus : 43 Diabetes means your blood glucose, or blood sugar, levels are too high. With type 2 diabetes, the more common type, your body does not make or use insulin well. Insulin is a hormone that helps glucose get into your cells to give them energy. Without insulin, too much glucose stays in your blood. Over time, high blood glucose can lead to serious problems with your heart, eyes, kidneys, nerves, and gums and teeth. You have a higher risk of type 2 diabetes if you are older, have obesity, have a family history of diabetes, or do not exercise. Having prediabetes also increases your risk. Prediabetes means that your blood sugar is higher than normal but not high enough to be called diabetes. If you are at risk for type 2 diabetes, you may be able to delay or prevent developing it by making some lifestyle changes. The symptoms of type 2 diabetes appear slowly. Some people do not notice symptoms at all. The symptoms can include Being very thirsty Urinating often Feeling very hungry or tired Losing weight without trying Having sores that heal slowly Having blurry eyesight Blood tests can show if you have diabetes. One type of test, the A1C, can also check on how you are managing your diabetes. Many people can manage their diabetes through healthy eating, physical activity, and blood glucose testing. Some people also need to take diabetes medicines. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Mellitus, Noninsulin-Dependent, also known as insulin resistance, is related to maturity-onset diabetes of the young and diabetes mellitus, and has symptoms including angina pectoris, tremor and equilibration disorder. An important gene associated with Diabetes Mellitus, Noninsulin-Dependent is IRS1 (Insulin Receptor Substrate 1), and among its related pathways/superpathways are Cell cycle and p53 signaling pathway. The drugs Linagliptin and Metformin have been mentioned in the context of this disorder. Affiliated tissues include Pancreas and Adipose, and related phenotypes are insulin resistance and type ii diabetes mellitus

UniProtKB/Swiss-Prot : 75 Diabetes mellitus, non-insulin-dependent: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

Genetics Home Reference : 25 Type 2 diabetes is a disorder characterized by abnormally high blood sugar levels. In this form of diabetes, the body stops using and making insulin properly. Insulin is a hormone produced in the pancreas that helps regulate blood sugar levels. Specifically, insulin controls how much glucose (a type of sugar) is passed from the blood into cells, where it is used as an energy source. When blood sugar levels are high (such as after a meal), the pancreas releases insulin to move the excess glucose into cells, which reduces the amount of glucose in the blood.

Disease Ontology : 12 A diabetes mellitus that involves high blood glucose resulting from cells fail to use insulin properly.

PubMed Health : 63 About type 2 diabetes: Type 2 diabetes (diabetes mellitus) is a metabolic disease that causes sugar to build up in the blood stream. The severity of diabetes can vary quite a bit: Some people only have to make minor changes to their lifestyle after they are diagnosed. Just losing a little weight and getting a bit more exercise may be enough for them to manage their diabetes. Other people who have type 2 diabetes need long-term treatment that involves taking tablets or insulin. It is then especially important for them to have a good understanding of their disease and know what they can do to stay healthy.There are two main types of diabetes. Type 1 diabetes usually develops in childhood or teenage years. This disease is a result of damage to the pancreas that leaves it producing either very little insulin or none at all.Things are different in type 2 diabetes, where insulin is made by the pancreas but the body’s cells gradually lose the ability to absorb and use the insulin. In the past, type 2 diabetes was often referred to as “adult-onset” diabetes because it is commonly diagnosed later in life. Type 2 diabetes is much more common than type 1 diabetes. About 90% of people who have diabetes have type 2 diabetes.

Wikipedia : 76 Diabetes mellitus... more...

Description from OMIM: 125853
Sources

Related Diseases for Diabetes Mellitus, Noninsulin-Dependent

About this section

Diseases in the Diabetes Mellitus, Noninsulin-Dependent family:

Diabetes Mellitus, Noninsulin-Dependent, 1 Diabetes Mellitus, Noninsulin-Dependent, 2
Diabetes Mellitus, Noninsulin-Dependent, 3 Diabetes Mellitus, Noninsulin-Dependent, 4
Diabetes Mellitus, Noninsulin-Dependent, 5

Diseases related to Diabetes Mellitus, Noninsulin-Dependent via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Related Disease Score Top Affiliating Genes
1 maturity-onset diabetes of the young 37.0 ABCC8 GCK HNF1B HNF4A IRS1 KCNJ11
2 diabetes mellitus 33.9 ABCC8 AKT2 GCGR GCK GPD2 HNF1B
3 lipodystrophy, familial partial, type 3 33.9 PPARG PPP1R3A
4 maturity-onset diabetes of the young, type 8, with exocrine dysfunction 12.7
5 maturity-onset diabetes of the young, type 9 12.7
6 maturity-onset diabetes of the young, type 3 12.7
7 maturity-onset diabetes of the young, type 1 12.7
8 insulin-resistant acanthosis nigricans, type a 12.6
9 diabetes mellitus, noninsulin-dependent, 1 12.5
10 diabetes mellitus, noninsulin-dependent, 5 12.5
11 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 12.5
12 diabetes mellitus, noninsulin-dependent, 2 12.5
13 diabetes mellitus, noninsulin-dependent, 4 12.5
14 diabetes mellitus, noninsulin-dependent, 3 12.4
15 diabetes mellitus, insulin-resistant, with acanthosis nigricans 12.4
16 insulin-resistance type b 12.4
17 intrauterine growth restriction-short stature-early adult-onset diabetes syndrome 12.2
18 hair-an syndrome 12.0
19 pseudoacromegaly with severe insulin resistance 12.0
20 insr-related severe syndromic insulin resistance 12.0
21 severe early-onset obesity-insulin resistance syndrome due to sh2b1 deficiency 12.0
22 microcephalic primordial dwarfism-insulin resistance syndrome 12.0
23 short fifth metacarpals-insulin resistance syndrome 12.0
24 glucose metabolism disease 11.9 ABCC8 GCK IRS1 KCNJ11 PPARG RETN
25 hyperglycemia 11.8 ABCC8 GCGR GCK INSR IRS1 KCNJ11
26 short syndrome 11.8
27 gestational diabetes 11.8 GCK HNF4A INSR IRS1 IRS2 KCNJ11
28 neonatal diabetes mellitus 11.7 ABCC8 GCK HNF1B KCNJ11 NEUROD1 SLC2A2
29 acquired metabolic disease 11.7 GCK IRS1 KCNJ11 PPARG RETN SLC2A2
30 body mass index quantitative trait locus 11 11.7 GCK INSR IRS1 IRS2 PPARG RETN
31 bangstad syndrome 11.6
32 monogenic diabetes 11.6 ABCC8 GCK HNF4A KCNJ11 PAX4
33 hyperinsulinemic hypoglycemia 11.6 ABCC8 GCK HNF4A INSR KCNJ11
34 hyperinsulinism 11.6 ABCC8 GCK HNF4A INSR KCNJ11
35 hypoglycemia 11.6 ABCC8 AKT2 GCK INSR KCNJ11
36 endocrine pancreas disease 11.6 ABCC8 GCK IRS1 KCNJ11
37 glucose intolerance 11.5 GCK INSR IRS1 RETN
38 munchausen by proxy 11.5 ABCC8 GCK KCNJ11
39 insulinoma 11.5 ABCC8 GCK SLC2A2 WFS1
40 factitious disorder 11.5 ABCC8 GCK KCNJ11
41 insulin-like growth factor i 11.4 AKT2 INSR IRS1 IRS2
42 hyperinsulinemic hypoglycemia, familial, 2 11.4 ABCC8 HNF4A KCNJ11
43 pancreatic agenesis 11.4 ABCC8 GCK KCNJ11
44 3-hydroxyacyl-coa dehydrogenase deficiency 11.3 GCK PPARG RETN
45 diabetes mellitus, permanent neonatal 11.3 ABCC8 GCK KCNJ11
46 diabetes mellitus, insulin-dependent 11.3 GCK NEUROD1 PAX4 WFS1
47 overnutrition 11.2 IRS1 PPARG RETN
48 maturity-onset diabetes of the young, type 2 11.1
49 autoimmune polyendocrine syndrome, type ii 11.1
50 diabetes and deafness, maternally inherited 11.1

Comorbidity relations with Diabetes Mellitus, Noninsulin-Dependent via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Ischemic Heart Disease Peripheral Vascular Disease
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Diabetes Mellitus, Noninsulin-Dependent:



Diseases related to Diabetes Mellitus, Noninsulin-Dependent
Sources

Symptoms & Phenotypes for Diabetes Mellitus, Noninsulin-Dependent

About this section

Symptoms via clinical synopsis from OMIM:

57
Endo:
noninsulin-dependent diabetes mellitus

Lab:
insulin resistance
decreased glucose disposal

Misc:
late onset


Clinical features from OMIM:

125853

Human phenotypes related to Diabetes Mellitus, Noninsulin-Dependent:

32
# Description HPO Frequency HPO Source Accession
1 insulin resistance 32 HP:0000855
2 type ii diabetes mellitus 32 HP:0005978

UMLS symptoms related to Diabetes Mellitus, Noninsulin-Dependent:


angina pectoris, tremor, equilibration disorder, symptoms

GenomeRNAi Phenotypes related to Diabetes Mellitus, Noninsulin-Dependent according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.54 MAPK8IP1
2 Decreased viability GR00221-A-1 10.54 PPARG AKT2 GCK INSR IRS1
3 Decreased viability GR00221-A-2 10.54 PPARG GCK INSR IRS1
4 Decreased viability GR00221-A-3 10.54 PPARG AKT2 GCK INSR
5 Decreased viability GR00221-A-4 10.54 MAPK8IP1 PPARG AKT2 GCK INSR
6 Decreased viability GR00231-A 10.54 GCK
7 Decreased viability GR00301-A 10.54 MAPK8IP1 AKT2
8 Decreased viability GR00342-S-2 10.54 IRS1
9 Decreased viability GR00342-S-3 10.54 AKT2 MAPK8IP1 IRS1
10 Decreased viability GR00402-S-2 10.54 MAPK8IP1 PPARG AKT2 GCK INSR IRS1
11 Decreased viability in esophageal squamous lineage GR00235-A 9.36 GCGR HNF1B HNF4A INSR MAPK8IP1 PAX4

MGI Mouse Phenotypes related to Diabetes Mellitus, Noninsulin-Dependent:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.3 AKT2 GCGR GCK GPD2 HNF1B INSR
2 growth/size/body region MP:0005378 10.28 AKT2 GCGR GCK GPD2 HNF1B IRS1
3 homeostasis/metabolism MP:0005376 10.26 PAX4 PPARG PPP1R3A RETN SLC2A2 SLC30A8
4 adipose tissue MP:0005375 10.16 AKT2 GCGR GPD2 INSR IRS1 IRS2
5 cellular MP:0005384 10.14 AKT2 GCGR HNF4A INSR IRS1 IRS2
6 behavior/neurological MP:0005386 10.13 GCGR GPD2 INSR IRS2 KCNJ11 MAPK8IP1
7 liver/biliary system MP:0005370 10 AKT2 GCGR GCK GPD2 HNF1B HNF4A
8 mortality/aging MP:0010768 9.86 IRS1 IRS2 KCNJ11 MAPK8IP1 NEUROD1 PAX4
9 muscle MP:0005369 9.28 AKT2 HNF1B INSR IRS1 IRS2 KCNJ11
Sources

Drugs & Therapeutics for Diabetes Mellitus, Noninsulin-Dependent

About this section

PubMedHealth treatment related to Diabetes Mellitus, Noninsulin-Dependent: 63

A number of factors influence which treatment approach for type 2 diabetes is most suitable: They include age, general physical condition, other health problems, life circumstances and personal goals.Sometimes just changing your lifestyle can have a positive effect: Losing weight and getting more exercise can make insulin more effective and lower blood sugar levels. Quitting smoking helps to reduce the risk of cardiovascular disease. Making these kinds of changes is sometimes enough to manage the condition and associated risks.If very overweight (obese) people find it hard to lose weight, surgical approaches such as stomach stapling may be an option.Some people depend on medication to regulate their blood sugar levels. The medication options include taking tablets, injecting insulin or medication called incretin mimetics (hormone-like substances that are designed to increase the body's insulin production). It's also possible to combine tablets and injections. The most common medications used to treat type 2 diabetes (antidiabetic drugs) are metformin and sulfonylureas. Newer antidiabetic drugs are also available – but there are still many unanswered questions about their effects.Depending on what other symptoms and illnesses a person has, different kinds of medication can be used to lower particular risks. For example, many people who have type 2 diabetes also have high blood pressure.The main medications that can lower the risk of cardiovascular diseaselower blood pressure (antihypertensives),prevent blood clotting (ASA, the drug in medications like Aspirin), orreduce cholesterol levels (statins).

Drugs for Diabetes Mellitus, Noninsulin-Dependent (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 668270-12-0 10096344
2
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
3
Voglibose Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83480-29-9 444020
4
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 160337-95-1
5
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 7440-66-6 23994
6
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 111025-46-8 4829
7
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 141758-74-9 15991534
8
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169148-63-4 5311023
9
Glipizide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29094-61-9 3478
10
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 361442-04-8 11243969
11
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 56180-94-0 441184
12
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
13
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 204656-20-2 44147092
14
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 133107-64-9
15
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 116094-23-6 16132418
16
Glimepiride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93479-97-1 3476
17
Clopidogrel Approved Phase 4,Phase 2,Not Applicable 120202-66-6, 113665-84-2 60606
18
Ramipril Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 87333-19-5 5362129
19
Ticlopidine Approved Phase 4,Phase 2 55142-85-3 5472
20
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 128-13-2 31401
21
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
22
Insulin glulisine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 207748-29-6
23
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
24
Fluvastatin Approved Phase 4,Phase 3 93957-54-1 1548972
25
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 137862-53-4 60846
26
Alogliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 850649-61-5 11450633
27
Canagliflozin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 842133-18-0
28
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274901-16-5 6918537
29
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
30
Gliclazide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21187-98-4 3475
31
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 88150-42-9 2162
32
Atenolol Approved Phase 4,Not Applicable 29122-68-7 2249
33
Clonidine Approved Phase 4,Phase 3 4205-90-7 2803
34
Doxazosin Approved Phase 4 74191-85-8 3157
35
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 54-31-9 3440
36
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-93-5 3639
37
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 138402-11-6 3749
38
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
39
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 75847-73-3 5362032 40466924
40
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Not Applicable 76420-72-9 6917719
41
AT-101 Approved, Investigational Phase 4,Not Applicable 90141-22-3, 652-67-5 12597
42
Isosorbide Dinitrate Approved, Investigational Phase 4,Not Applicable 87-33-2 6883
43
Nitric Oxide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 10102-43-9 145068 160954
44
Ticagrelor Approved Phase 4,Phase 3,Not Applicable 274693-27-5 9871419
45
Repaglinide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 135062-02-1 65981
46
Glyburide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 10238-21-8 3488
47
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-18-4 6010
48
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
49
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 315-37-7 9416
50
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 5949-44-0

Interventional clinical trials:

(show top 50) (show all 9948)
# Name Status NCT ID Phase Drugs
1 Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
2 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4 Sitagliptin;Placebo
3 Continuous Glucose Monitoring in Patients With Type 2 Diabetes Unknown status NCT00529815 Phase 4
4 The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient Unknown status NCT02261545 Phase 4
5 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
6 Multifactorial Intervention in Type 2 Diabetes - Italy Unknown status NCT01240070 Phase 4
7 Comparison of the Efficacy and Safety Between Pioglitazone and Placebo Added to Combination Therapy in Type 2 Diabetes Unknown status NCT00991055 Phase 4 Pioglitazone
8 Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes Unknown status NCT01435980 Phase 4 Exenatide
9 Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 Diabetes Unknown status NCT01281605 Phase 4
10 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
11 Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes Unknown status NCT01758471 Phase 4 Glipizide;Acarbose
12 Type 2 Diabetes Mellitus and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
13 Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes Unknown status NCT02344186 Phase 4 Liraglutide
14 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
15 Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes Unknown status NCT02449603 Phase 4 Exenatide;Biphasic insulin Aspart 30
16 Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices Unknown status NCT02361489 Phase 4
17 Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes Unknown status NCT02605772 Phase 4 Acarbose;Metformin;Saxagliptin
18 Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes Unknown status NCT02372955 Phase 4 dapagliflozin;glimpiride
19 Insulin Effects on Metabolism and Cardiovascular Function in Type 2 Diabetes Unknown status NCT00747409 Phase 4 insulin aspart and detemir (NovoRapid, Levemir);human regular insulin and NPH insulin (Actrapid, Protaphne)
20 Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients Unknown status NCT00399204 Phase 4 Pioglitazone vs Metformin
21 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
22 Chronic Cold Acclimation Stimulates the Browning of Subcutaneous White Adipose in Patients With Type 2 Diabetes Mellitus Unknown status NCT02775253 Phase 4
23 Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy Unknown status NCT02129985 Phase 4 Exenatide;Metformin
24 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
25 the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes Unknown status NCT01876563 Phase 4
26 Thyroid Study Type 2 Diabetes Mellitus (T2DM) Unknown status NCT01379170 Phase 4 Euthyrox (levothyroxine)
27 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
28 The Impact of Omega-3 Supplementation on Gene Expression in Type 2 Diabetics Unknown status NCT01478776 Phase 4
29 A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes Unknown status NCT02606617 Phase 4 Mosapride;Placebo
30 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
31 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
32 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
33 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
34 Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin Unknown status NCT02426294 Phase 4 Pioglitazone;Glimepiride
35 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4 Linagliptin;Glimepiride
36 Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study) Unknown status NCT02512523 Phase 4 Teneligliptin;Sitagliptin
37 Vascular Effects of Sitagliptin in Diabetes Mellitus Unknown status NCT01096277 Phase 4 Sitagliptin;Placebo
38 Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
39 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
40 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
41 Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes Unknown status NCT01978405 Phase 4 Alpha lipoic acid
42 Metabolomic Variations in the Saxagliptin-Treated Type 2 Diabetes Mellitus Patients Unknown status NCT01768208 Phase 4 Saxagliptin
43 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
44 the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin Unknown status NCT02438397 Phase 4 premix insulin;metformin;Acarbose
45 Glycemic Durability After Metformin Failure Unknown status NCT02142309 Phase 4 Glimepiride;Vildagliptin;Pioglitazone;Canagliflozin
46 Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes Unknown status NCT02583438 Phase 4 Saxagliptin (Bristol-Myers Squibb Company)
47 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4 Aliskiren + Valsartan
48 Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells Unknown status NCT00523393 Phase 4 Insulin Glargin;Human Insulin
49 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
50 Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients Unknown status NCT02219750 Phase 4 switch twice-daily insulin

Search NIH Clinical Center for Diabetes Mellitus, Noninsulin-Dependent

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diabetes Mellitus, Noninsulin-Dependent cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Diabetes Mellitus, Noninsulin-Dependent:
Bone marrow-derived mesenchymal stem cells for treatment of type 2 diabetes mellitus
Bone marrow-derived stem cells for treatment of type 2 diabetes mellitus
Hematopoietic stem cells for limb ischemia and diabetic neuropathy
Mesenchymal precursor cells for type 2 diabetes
Stem cells educator of T cells for treatment of type 2 diabetes mellitus
StemGenex
Embryonic/Adult Cultured Cells Related to Diabetes Mellitus, Noninsulin-Dependent:
Bone marrow-derived mesenchymal stem cells (family)
Bone marrow-derived mononuclear cells PMIDs: 23561959 19686048
Peripheral blood-derived hematopoietic stem cells (family)
Mesenchymal Precursor Cells (STRO-3 selected)
Umbilical cord blood-derived multipotent stem cells
Regulatory T lymphocytes
Adipose-derived stem cells (StemGenex

Cochrane evidence based reviews: diabetes mellitus, type 2

Sources

Genetic Tests for Diabetes Mellitus, Noninsulin-Dependent

About this section

Genetic tests related to Diabetes Mellitus, Noninsulin-Dependent:

# Genetic test Affiliating Genes
1 Diabetes Mellitus Type 2 29 ABCC8 AKT2 CDKAL1 ENPP1 GCGR GCK GPD2 HMGA1 HNF1A HNF1B HNF4A IGF2BP2 IRS1 IRS2 KCNJ11 LIPC MAPK8IP1 MTNR1B NEUROD1 PAX4 PDX1 PPARG PPP1R3A PTPN1 RETN SLC2A2 SLC30A8 TCF7L2 WFS1
2 Insulin Resistance 29
Sources

Anatomical Context for Diabetes Mellitus, Noninsulin-Dependent

About this section

MalaCards organs/tissues related to Diabetes Mellitus, Noninsulin-Dependent:

41
Liver, Endothelial, Ovary, Heart, Kidney, Skeletal Muscle, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Diabetes Mellitus, Noninsulin-Dependent:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Islets of Langerhans Mature Beta Cells Potential therapeutic candidate, affected by disease
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate
Sources

Publications for Diabetes Mellitus, Noninsulin-Dependent

About this section

Articles related to Diabetes Mellitus, Noninsulin-Dependent:

(show top 50) (show all 6194)
# Title Authors Year
1
Association of abnormal glucose metabolism and insulin resistance in patients with atypical and typical endometrial cancer. ( 29434922 )
2018
2
Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation. ( 29429367 )
2018
3
Correction to: Seyyed Abootorabi et al., The effect of vitamin D supplementation on insulin resistance, visceral fat and adiponectin in vitamin D deficient women with polycystic ovary syndrome: a randomized placebo-controlled trial. ( 29447022 )
2018
4
Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver. ( 29719598 )
2018
5
Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance. ( 29068242 )
2018
6
Effects of isomaltulose on insulin resistance and metabolites in patients with nona89alcoholic fatty liver disease: A metabolomic analysis. ( 29956790 )
2018
7
Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). ( 29084736 )
2018
8
The Role of Insulin Resistance/Hyperinsulinism on the Rising Trend of Thyroid and Adrenal Nodular Disease in the Current Environment. ( 29495350 )
2018
9
Abdominal fat deposits determined by magnetic resonance imaging in relation to leptin and vaspin levels as well as insulin resistance in the general adult population. ( 28925406 )
2018
10
Preventive effects of <i>Salvia officinalis</i> leaf extract on insulin resistance and inflammation in a model of high fat diet-induced obesity in mice that responds to rosiglitazone. ( 29333341 )
2018
11
Limitations of insulin resistance assessment in polycystic ovary syndrome. ( 29436386 )
2018
12
Circulating ApoJ is closely associated with insulin resistance in human subjects. ( 28986164 )
2018
13
Insulinlike Growth Factor-Binding Protein-1 Improves Vascular Endothelial Repair in Male Mice in the Setting of Insulin Resistance. ( 29186427 )
2018
14
Relationship Between Serum Macrophage Migration Inhibitory Factor Level and Insulin Resistance, High-Sensitivity C-Reactive Protein and Visceral Fat Mass in Prediabetes. ( 29289260 )
2018
15
Plasma Levels of Myonectin But Not Myostatin or Fibroblast-Derived Growth Factor 21 Are Associated with Insulin Resistance in Adult Humans without Diabetes Mellitus. ( 29445355 )
2018
16
Severe insulin resistance in disguise: A familial case of reactive hypoglycemia associated with a novel heterozygous INSR mutation. ( 29411486 )
2018
17
Melatonin Treatment Improves Insulin Resistance and Pigmentation in Obese Patients with Acanthosis Nigricans. ( 29706998 )
2018
18
Invited commentary in response to: selenium supplementation lowers insulin resistance and markers of cardio-metabolic risk in patients with congestive heart failure: a randomised, double-blind, placebo-controlled trial. ( 29936919 )
2018
19
Selenium supplementation lowers insulin resistance and markers of cardio-metabolic risk in patients with congestive heart failure: a randomised, double-blind, placebo-controlled trial. ( 29936923 )
2018
20
Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. ( 29404514 )
2018
21
The effect of non anti TNF targeting biologics and small molecules on insulin resistance in inflammatory arthritis. ( 29452240 )
2018
22
Association of paraoxonase-1 gene polymorphisms with insulin resistance in South Indian population. ( 29409844 )
2018
23
Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs. ( 29451090 )
2018
24
Insulin-resistance in glycogen storage disease type Ia: linking carbohydrates and mitochondria? ( 29435782 )
2018
25
Metabolic patterns in insulin-resistant male hypogonadism. ( 29867095 )
2018
26
Maternal obesity increases insulin resistance, low-grade inflammation and osteochondrosis lesions in foals and yearlings until 18 months of age. ( 29373573 )
2018
27
Insulin resistance depends on GH counter-regulation in two syndromes of short stature. ( 29306561 )
2018
28
Epigenetic programming at the Mogat1 locus may link neonatal overnutrition with long-term hepatic steatosis and insulin resistance. ( 29812971 )
2018
29
Elevated CD14<sup>++</sup>CD16<sup>+</sup>Monocytes in Hyperhomocysteinemia-Associated Insulin Resistance in Polycystic Ovary Syndrome. ( 29439619 )
2018
30
Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. ( 29960703 )
2018
31
Insulin Resistance Associated With Differentiated Thyroid Carcinoma: Penalized Conditional Logistic Regression Analysis of a Matched Case-Control Study Data. ( 29696038 )
2018
32
Blockade of Endothelin-1 Receptor Type B Ameliorates Glucose Intolerance and Insulin Resistance in a Mouse Model of Obstructive Sleep Apnea. ( 29896159 )
2018
33
Higher Concentrations of BCAAs and 3-HIB Are Associated with Insulin Resistance in the Transition from Gestational Diabetes to Type 2 Diabetes. ( 29967793 )
2018
34
The effects of synbiotic supplementation on insulin resistance/sensitivity, lipid profile and total antioxidant capacity in women with gestational diabetes mellitus: a randomized double blind placebo controlled clinical trial. ( 29432772 )
2018
35
Insulin Resistance is Associated with Chronic Laryngitis in Korean Women. ( 29582885 )
2018
36
Low Plasma Adiponectin Concentrations Predict Increases in Visceral Adiposity and Insulin Resistance. ( 29029184 )
2017
37
AlstrAPm syndrome: A novel mutation in Saudi girl with insulin-resistant diabetes. ( 28272210 )
2017
38
Macrophage function in obesity-induced inflammation and insulin resistance. ( 28233125 )
2017
39
Serum Quantitative Proteomic Analysis Reveals Soluble EGFR To Be a Marker of Insulin Resistance in Male Mice and Humans. ( 29028997 )
2017
40
Myeloid Sirtuin 6 Deficiency Causes Insulin Resistance in High-Fat Diet-Fed Mice by Eliciting Macrophage Polarization Toward an M1 Phenotype. ( 28607107 )
2017
41
Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. ( 29161258 )
2017
42
Salt-inducible kinase 2 and -3 are downregulated in adipose tissue from obese or insulin-resistant individuals: implications for insulin signalling and glucose uptake in human adipocytes. ( 27807598 )
2017
43
Short-chain fatty acids and inulin, but not guar gum, prevent diet-induced obesity and insulin resistance through differential mechanisms in mice. ( 28733671 )
2017
44
Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. ( 27407018 )
2017
45
Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty. ( 28443256 )
2017
46
Relation of Trp64Arg polymorphism of beta 3 adrenoreceptor gene with metabolic syndrome and insulin resistance in obese women. ( 28421794 )
2017
47
USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity. ( 28718215 )
2017
48
<i>Berberis integerrima</i> ameliorates insulin resistance in high- fructose-fed insulin-resistant rats. ( 29147484 )
2017
49
Brain natriuretic peptide and insulin resistance in older adults. ( 27101535 )
2017
50
Thyroid Signaling, Insulin Resistance, and 2 Diabetes Mellitus: A Mendelian Randomization Study. ( 28323940 )
2017